News
03-23-2010, 07:10 AM
Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.
More... (http://www.news-medical.net/news/20100323/Garnet-BioTherapeutics-commences-treatment-in-GBT009-trial-for-incisional-wounds-following-breast-reconstruction-surgery.aspx)
More... (http://www.news-medical.net/news/20100323/Garnet-BioTherapeutics-commences-treatment-in-GBT009-trial-for-incisional-wounds-following-breast-reconstruction-surgery.aspx)